22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
22:15 , Jan 6, 2017 |  BioCentury  |  Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Financial News

Bora Pharmaceuticals proposes IPO

Bora Pharmaceuticals Co. Ltd. (TPEx-E:6472), Taipei, Taiwan   Business: Neurology, Supply/Service   Date announced: 2016-09-23   Type: IPO   To be raised: TBD   Shares: TBD   Price: TBD   Underwriter: Taishin Securities   Note:...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

Fundamental reset

Steve Edelson, Senior Editor   After three months of carnage, buysiders acknowledge their conservative prediction of biotech keeping pace with the broader markets is unlikely to occur this year. Instead, investors are looking for the...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Curbed enthusiasm

Following three years of investor exuberance manifested in gains of at least 115% in biotech indices, buysiders say a good 2016 would see biotech merely keeping pace with the broader markets. Nobody is calling an...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Financial News

Bora Pharmaceuticals proposes IPO

Bora Pharmaceuticals Co. Ltd. (TPEx-E:6472), Taipei, Taiwan   Business: Neurology, Supply/Service   Date announced: 2015-08-31   Type: IPO   To be raised: TBD   Shares: TBD   Price: TBD   Underwriter: Taishin Securities   Note:...